Accessibility StatementSkip Navigation - New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs - - Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in an ESMO Presidential Symposium - TOKYO, Oct. 1, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present ten abstracts from our ...

Core Insights - Veeva Systems and Sarah Cannon Research Institute (SCRI) have formed a strategic collaboration to enhance the efficiency of oncology clinical trials across SCRI's 200+ research sites [1][2] - The adoption of Veeva Clinical Platform aims to unify SCRI's contract research organization (CRO) and site management organization (SMO) for improved data flow and trial processes [1][2] Company Overview - Sarah Cannon Research Institute is a leading oncology research organization with a focus on community-based clinical trials, having conducted over 850 first-in-human clinical trials and contributed to the majority of new cancer therapies approved by the FDA in the last decade [4] - Veeva Systems is recognized as the global leader in cloud software for the life sciences industry, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [5] Technology and Innovation - The Veeva Clinical Platform is a comprehensive solution that integrates various clinical operations and data applications, streamlining the clinical trial process from start to finish [3] - The collaboration is expected to standardize operations on a single platform, enabling SCRI to deliver faster and more cost-effective clinical trials [3]